Fisetin in Mild Alzheimer's Disease (FIS-AD)

Sunnybrook Health Sciences Centre

Status and phase

Not yet enrolling

Phase 2

Conditions

Alzheimer Dementia

Alzheimer Disease

Alzheimer s Disease

Neurocognitive Disorders, Mild

Neurocognitive Disorder

Mild Cognitive Disorder

Alzheimer Dementia (AD)

Treatments

Other: Fisetin

Study type

Interventional

Funder types

Other

Identifiers

NCT07279714

6705

Details and patient eligibility

About

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Enrollment

5 estimated patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
Moca score of 11 or higher
Stable psychotropics and cognitive enhancing medications

Exclusion criteria

Known hypersensitivity or allergy to fisetin
Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
Unstable medical disorders
Ongoing treatment for active infection with antibiotics/antifungals
Ongoing treatment for cancer
Active alcohol or substance use disorder
Recent active bleeding
Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
Other neurologic or neurodegenerative conditions impacting cognition
Active Major Depressive Episode, active suicidal thoughts or psychosis
Any thing that would preclude the ability to undergo an MRI scan